1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalizedpatients with 2019 novel coronavirus-infected pneumonia in Wuhan,China. JAMA. 2020;323(11):1061-1069.
2. Demirhan R, Cimenoglu B, Yilmaz E. The effects of hospitalorganization on treatment during COVID-19 pandemic. South Clin IstEuras. 2020;31(2):89-95.
3. World Health Organization. Coronavirus disease 2019 (COVID19)Situation Report 28. https://www.who.int/docs/defaultsource/coronav iruse/situation-repor ts/2020 0217-sitrep-28-cov id19.pdf?sfvrsn=a19cf2ad_2 Accessed March 9, 2022
4. Banu K. Clinical findings of ¬ e COVID-19 in the adult group. JBiotechnol Strategic Health Res. 2020;1:85-90.
5. Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small dropletaerosols in poorly ventilated spaces and SARS-CoV-2 transmission.Lancet Respir Med. 2020;8(7):658-659.
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortalityof adult inpatients with COVID-19 in Wuhan, China: a retrospectivecohort study. Lancet. 2020;395:1054-1062.
7. Wu Z, McGoogan JM. Characteristics of and important lessons fromthe coronavirus disease 2019 (COVID-19) outbreak in China: summaryof a report of 72 314 cases from the Chinese Center for Disease Controland Prevention. JAMA. 2020;323(13):1239-1242.
8. Ufuk F, Savaş R. Chest CT features of the novel coronavirusdisease(COVID-19). Turk J Med Sci. 2020;50(4):664-678.
9. Akçay S, Özlü T, Yılmaz A. Radiological approaches to COVID-19pneumonia. Turk J Med Sci. 2020;50(9):604-610.
10. Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaignguidelines on the management of adults with coronavirus disease 2019(COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219-e234.
11. Franquet T. Imaging of pulmonary viral pneumonia. Radiol.2011;260(1):18-39.
12. Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CTfeatures of viral pneumonia. Radiograph. 2018;38(3):719-739.
13. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL,Remy J. Fleischner Society: glossary of terms for thoracic imaging.Radiol. 2008;246(3):697-722.
14. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CTduring recovery from 2019 novel coronavirus (COVID-19) pneumonia.Radiol. 2020;295(3):715-721.
15. Meeting the challenge of long COVID (editorial). Nat Med.2020;26(12):1803.
16. Brodin P. Immune determinants of COVID-19 disease presentationand severity. Nat Med. 2021;27(1):28-33.
17. Brenner DR, Scherer D, Muir K, et al. A review of the application ofinflammatory biomarkers in epidemiologic cancer research. CancerEpidemiol Biomarkers Prev. 2014;23(9):1729-1751.
18. Wang T, Du Z, Fengxue Zhu, et al. Comorbidities and multi-organinjuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52.
19. Tülay ÜU , Mesut D , Heval CB. Diagnostic utility and prognostic valueof basic laboratory parameters in COVID-19. Klimik J. 2021;34(3):174-181.
20. Liu D, Zhang W, Pan F, et al. The pulmonary sequalae in dischargedpatients with COVID- 19: a short-term observational study. Respir Res.2020;21(1):125.
21. Zhao YM, Shang YM, Song WB, et al. Follow-up study of thepulmonary function and related physiological characteristics ofCOVID-19 survivors three months after recovery. EClinicalMedicine.2020;25:100463.
22. Barisione E, Grillo F, Bal L, et al. Fibrotic progression and radiologiccorrelation inmatched lung samples from COVID-19 post-mortems.Virchows Arch. 2020;478(3):471-485.
23. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findingsin a series of COVID-19 cases from northern Italy: a two-centredescriptive study. Lancet Infect Dis. 2020;20(10):1135-1140.
24. Gentile F, Aimo A, Forfori F, et al. COVID-19 and risk of pulmonaryfibrosis: the importance of planning ahead. Eur J Preven Cardiol.2020;27(13):1442-1446.
25. Huang W,Wu Q, Chen Z, et al. The potential indicators for pulmonaryfibrosis in survivors of severe COVID-19. J Infect. 2021;82(2):e5-e7.
26. Kucuk C,Turkkani MH, Arda K. A case report of reversiblebronchiectasis in an adult: pseudobronchiectasis. Respir Med Case Rep.2019;26:315-316.
27. Lechowicz K, Drozdzal S, Machaj F, et al. COVID-19: The potentialtreatment of pulmonary fibrosis associated with SARS-CoV-2 infection.J Clin Med. 2020;9(6):1917.
28. Hu T, Liu Y, Zhao M, et al. A comparison of COVID-19, SARS andMERS. Peer J. 2020;8:e9725.
29. Shaw B, Daskareh M, Gholamrezanezhad A. The lingeringmanifestations of COVID-19 during and after convalescence: updateon long-term pulmonary consequences of coronavirus disease 2019(COVID-19). Radiol Med. 2020;126(1);40-46.